WAUKEGAN, Ill.--(BUSINESS WIRE)--Sept. 19, 2006--Ferro Pfanstiehl Laboratories, Inc., part of the Organic Specialties Group of Ferro Corporation (NYSE:FOE), has commissioned a new validated cGMP supercritical fluid-based particle engineering pilot facility. The facility brings additional expertise in particle sizing, purification and formulation to fee-for-service pharmaceutical and biopharmaceutical customers. It will provide ICH Q7A-compliant small-scale manufacturing of drug particles and compounds for use in Phase I and II clinical trials and feasibility studies of engineered particles for any desired drug delivery application.
